Biotech Stocks Facing FDA Decision In June 2021

1 / 16

In May, two novel drugs secured regulatory approval in the U.S. - Johnson & Johnson’s Rybrevant and Apellis Pharmaceuticals’ Empaveli - compared to 6 during the same period last year.

Rybrevant was approved on May 21 as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Empaveli was approved on May 14 to treat adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening blood disease.